[Corrigendum] MicroRNA-375 inhibits glioma cell proliferation and migration by downregulating RWDD3 in vitro
Retraction in: /10.3892/or.2020.7785
Affiliations: Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Department of Neurosurgery, People's Hospital of Nanchang County, Nanchang, Jiangxi 330200, P.R. China
- Published online on: August 18, 2020 https://doi.org/10.3892/or.2020.7738
- Pages: 2317-2318
Copyright : © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Rep 39: [Related article:] 1825-1834, 2018; DOI: 10.3892/or.2018.6261
The authors of the above article drew to our attention that they had identified three instances of data overlapping between data panels, suggesting that data purportedly showing results obtained under different experimental conditions had been derived from the same original source. Comparing between the two figures, two pairs of panels in Fig. 4B (the Mimics control and blank experiments for the U87 and U251 cell lines) were shown to be overlapping, and a further pair of panels showed overlapping data in Fig. 6B (the data panels for the miR-375 mi + .pCDNA/RWDD3 and miR-375 mi + .pCDNA experiments for the U87 cell line).
(A) Overexpression of miR-375 inhibits the proliferation and migration of glioma cells. (B) CCK-8 proliferation assays were used to detect cell proliferation after transfection with miR-375 mimics and controls. (C) Transwell assays were used to investigate cell invasion. Scratch assays were used to investigate cell migration. Values are presented as the mean ± SD of three separate experiments. ***P<0.001.
Overexpression of RWDD3 enhances glioma cell proliferation and migration reduced by miR-375. (A) CCK-8 proliferation assays were used to detect cell proliferation after co-transfection with miR-375 mimics and pcDNA/RWDD3. (B) Transwell assays were used to investigate migration. (C) Scratch assays were used to investigate migration. Values are represented as mean ± SD of three separate experiments. ***P<0.001. RWDD3, RWD domain-containing sumoylation enhancer.
The authors were able to re-examine the original data files and retrieve the correct data panels. The errors in these figures arose through inadvertently assembling Figs. 4 and 6 incorrectly. The revised versions of Figs. 4 and 6, featuring the corrected data panels for the Mimics control and blank experiments for the U87 and U251 cell lines in Fig. 4B, and the correct data for the U87 cell line in Fig. 6B, are shown opposite and on the next page, respectively. Note that the corrections to the data shown in these Figures do not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this Corrigendum, and apologize to the readership for any inconvenience caused.